Fox Chase Cancer Center News

Joshua E. Meyer, MD, FASTRO, Vice Chair of Translational Research and a Professor in the Department of Radiation Oncology at Fox Chase Cancer Center, has been named a Fellow of the American Society for Radiation Oncology (ASTRO) at the organization’s 2025 Annual Meeting being held in San Francisco.

Researchers at Fox Chase Cancer Center were part of an international team that found a steep rise in kidney cancer cases will be driven largely by preventable risk factors such as obesity, smoking, lack of exercise, diabetes, and hypertension.

Jeffrey Farma, MD, FACS, Chair and Professor in the Department of Surgery at Fox Chase Cancer Center, has been elected to serve as the Society of University Surgeons (SUS) representative to the Association of American Medical Colleges’ (AAMC) Council of Faculty and Academic Societies (CFAS). Farma will also join the SUS Executive Council.

Roland L. Dunbrack Jr., PhD, Professor and Co-leader of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center and Founding Director of the Fox Chase Molecular Modeling Facility, has been honored with the 2026 DeLano Award for Computational Biosciences from the American Society for Biochemistry and Molecular Biology (ASBMB).

Jennifer Kelly, BSN, RN, CURN, a nurse with the Fox Chase-Temple Urologic Institute, has become the first nurse in the Temple Health system to earn certification from the Society of Urologic Nurses & Associates (SUNA).

The National Accreditation Program for Breast Centers (NAPBC) has renewed Fox Chase Cancer Center’s accreditation, making it the sixth consecutive time Fox Chase has been honored with this distinction.

Researchers at Fox Chase Cancer Center received a prestigious Director’s Discretionary Allocation Award from Argonne National Laboratory, part of the U.S. Department of Energy. The allocation supports the Melanoma-Immune Checkpoint Blockade project (ICB), a Fox Chase initiative aimed at advancing research in melanoma immunotherapy.

In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts, a phenomenon they describe as “cell-in-cell.”